Aesthetic Medical International Holdings Group Limited

Aesthetic Medical International Holdings Group Limited

AIH
Aesthetic Medical International Holdings Group LimitedUS flagNASDAQ Global Market
0.33
USD
-0.17
- -
15.93MMarket Cap
No data availableFinancial data will appear here once available

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

APIChat
CEO
Pengwu Zhou
Full Time Employees
1,286
Sector
Healthcare
Industry
Medical - Care Facilities
Address
1122 Nanshan Boulevard Shenzhen People's Republic of China 518052
IPO Date
Oct 25, 2019
Business
Aesthetic Medical International Holdings Group Limited Aesthetic Medical International Holdings Group Limited (AIH), known as Peng'ai in China, is a leading provider of aesthetic medical services primarily in the People's Republic of China. The company operates approximately 15 treatment centers concentrated in major cities, with a focus on the Guangdong-Hong Kong-Macau Greater Bay Area and the Yangtze River Delta region; it also maintains a presence in Singapore. Founded in 1997 and headquartered in Shenzhen, China, AIH offers one-stop aesthetic solutions leveraging over 20 years of clinical experience, including surgical aesthetic treatments such as double eyelid surgery, rhinoplasty, breast augmentation, liposuction, and facelifts; non-surgical minimally invasive and energy-based treatments utilizing laser, ultrasound, and ultraviolet light technologies; and general healthcare services encompassing internal medicine, traditional Chinese medicine, aesthetic dentistry, dermatology, urology, gynecology, obstetrics, and hair loss treatments. In recent developments, the company transitioned its American Depositary Shares from Nasdaq to trading on the OTCQX Best Market in 2024 following a delisting determination by the Nasdaq Hearings Panel in May 2024, after receiving conditional continued listing through September 2024; additionally, in 2022, control was acquired by entities linked to the Lafang family, including Australia Wanda International Company Limited and Hainan Oriental Jiechuang Investment Partnership, through share purchases and subscriptions totaling RMB 270 million.

Company News

APIChat
  • Marimaca Copper Announces the Appointment of Kieran Daly to its Board of Directors

  • Marimaca Copper Announces C$68 Million Strategic Investment by Assore International Holdings (AIH) Including Private Placements Totaling C$30.3 Million led by AIH

  • Aesthetic Medical International Holdings Group Ltd. Announces the Commencement of OTCQX Trading

  • Aesthetic Medical International Holdings Group Ltd. Announces Receipt of Delisting Decision from the Nasdaq Hearings Panel

  • Aesthetic Medical International Holdings Group Ltd. Announces Receipt of Decision from the Nasdaq Hearings Panel for Conditional Continued Listing

  • Aesthetic Medical International to Announce FY2023 Annual Report on April 25, 2024

  • Why Is Aesthetic Medical (AIH) Stock Up 44% Today?

  • Aesthetic Medical International Holdings Group Ltd. Announces Receipt of a Letter of Expected Delisting Determination From Nasdaq Staff and Intention to Request a Hearing before the Nasdaq Hearings Panel

  • Aesthetic Medical International Announces Change of Auditor and Change of Director

  • Aesthetic Medical International Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

  • Aesthetic Medical International Reports First Half of 2023 Unaudited Financial Results

  • Aesthetic Medical International Announces (i) Closing of Share Transfer, Issue of Conversion Shares, and Issue of Warrants, (ii) Resignations and Appointment of Directors, (iii) Release of Share Pledge, and (iv) Entry into certain Contractual Arrangements with respect to Equity Interests

  • Aesthetic Medical International to Announce First Quarter 2023 Unaudited Financial Results on May 17, 2023

  • Aesthetic Medical International to Announce FY2022 Annual Report on April 21, 2023

  • Aesthetic Medical International Holdings Group Limited (AIH) Q3 2022 Earnings Call Transcript

  • Aesthetic Medical International to Announce Third Quarter 2022 Unaudited Financial Results on November 29, 2022

  • Aesthetic Medical International Holdings Group Limited (AIH) CEO Pengwu Zhou on Q2 2022 Results - Earnings Call Transcript

  • Aesthetic Medical International to Announce Unaudited Financial Results for the First Half of 2022 on August 17, 2022

  • Aesthetic Medical International Holdings Group Limited (AIH) CEO Dr. Pengwu Zhou on Q2 2021 Results - Earnings Call Transcript

  • Aesthetic Medical International to Announce Unaudited Financial Results for the Second Quarter and First Half of 2021 on November 16, 2021